Your browser is no longer supported. Please, upgrade your browser.
Settings
SRNE Sorrento Therapeutics, Inc. daily Stock Chart
SRNE [NASD]
Sorrento Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.61 Insider Own34.21% Shs Outstand216.96M Perf Week49.21%
Market Cap2.35B Forward P/E2.74 EPS next Y3.45 Insider Trans0.00% Shs Float213.79M Perf Month-14.74%
Income-270.20M PEG- EPS next Q-0.21 Inst Own24.50% Short Float34.31% Perf Quarter96.46%
Sales35.50M P/S66.15 EPS this Y-14.80% Inst Trans84.32% Short Ratio1.72 Perf Half Y360.00%
Book/sh0.63 P/B14.97 EPS next Y-30.54% ROA-49.40% Target Price- Perf Year313.60%
Cash/sh- P/C- EPS next 5Y37.00% ROE-297.90% 52W Range1.39 - 19.39 Perf YTD178.99%
Dividend- P/FCF- EPS past 5Y-11.10% ROI-91.30% 52W High-51.37% Beta2.89
Dividend %- Quick Ratio0.60 Sales past 5Y52.40% Gross Margin68.10% 52W Low578.42% ATR1.33
Employees310 Current Ratio0.60 Sales Q/Q38.50% Oper. Margin- RSI (14)57.22 Volatility17.56% 12.92%
OptionableYes Debt/Eq1.21 EPS Q/Q22.60% Profit Margin- Rel Volume0.82 Prev Close9.48
ShortableYes LT Debt/Eq1.07 Earnings- Payout- Avg Volume42.58M Price9.43
Recom2.00 SMA2020.84% SMA502.77% SMA20091.02% Volume34,903,043 Change-0.53%
Jul-31-20Reiterated H.C. Wainwright Buy $24 → $30
May-26-20Initiated Dawson James Buy $24
Oct-07-19Initiated JMP Securities Mkt Outperform $21
Jun-28-18Initiated B. Riley FBR, Inc. Buy $14.25
Jan-16-18Reiterated H.C. Wainwright Buy $20 → $30
May-22-17Reiterated Rodman & Renshaw Buy $30 → $20
May-22-17Reiterated FBR & Co. Outperform $13 → $9
Oct-03-16Initiated ROTH Capital Buy
Apr-06-16Reiterated FBR Capital Outperform $21 → $16
Mar-16-16Reiterated FBR Capital Outperform $22 → $21
Dec-22-15Initiated FBR Capital Outperform $22
Dec-07-15Resumed Rodman & Renshaw Buy $45
Aug-03-15Resumed MLV & Co Buy $34
Jul-29-15Reiterated Brean Capital Buy $17 → $26
May-28-15Initiated Brean Capital Buy $17
Mar-17-15Reiterated H.C. Wainwright Buy $13 → $20
Oct-02-14Initiated H.C. Wainwright Buy $11
Jun-19-14Initiated MLV & Co Buy $9
Dec-03-13Initiated Aegis Capital Buy $40
Nov-21-13Initiated CRT Capital Buy $11
Sep-20-20 08:23AM  
Sep-18-20 01:13PM  
09:32AM  
09:26AM  
08:42AM  
Sep-17-20 04:22PM  
12:56PM  
11:06AM  
11:00AM  
09:56AM  
09:24AM  
08:55AM  
Sep-16-20 09:30PM  
Sep-14-20 10:01AM  
06:00AM  
Sep-09-20 02:10PM  
Sep-03-20 07:50AM  
06:10AM  
Sep-02-20 12:26PM  
09:00AM  
Aug-31-20 12:34PM  
Aug-29-20 06:09AM  
Aug-27-20 06:22AM  
Aug-26-20 02:15PM  
11:06AM  
Aug-25-20 08:56AM  
Aug-24-20 11:38AM  
Aug-21-20 09:30AM  
08:23AM  
07:43AM  
07:36AM  
04:39AM  
Aug-20-20 04:05PM  
Aug-19-20 04:42PM  
02:25PM  
11:30AM  
09:00AM  
07:32AM  
03:36AM  
02:35AM  
Aug-18-20 05:57PM  
07:03AM  
06:08AM  
Aug-17-20 06:39PM  
11:45AM  
Aug-13-20 03:24PM  
02:01PM  
07:06AM  
Aug-12-20 07:51PM  
12:47PM  
06:50AM  
Aug-11-20 06:03PM  
11:18AM  
10:09AM  
Aug-09-20 11:11AM  
Aug-07-20 02:01PM  
12:30PM  
10:35AM  
06:16AM  
Aug-05-20 10:57AM  
07:13AM  
Aug-04-20 06:28PM  
12:20PM  
Aug-03-20 05:18PM  
Jul-31-20 05:52PM  
Jul-29-20 10:34AM  
08:01AM  
Jul-27-20 01:11PM  
11:40AM  
11:39AM  
11:30AM  
10:50AM  
10:16AM  
06:20AM  
Jul-26-20 09:45AM  
Jul-25-20 02:36PM  
Jul-24-20 08:44PM  
04:33PM  
03:46PM  
12:59PM  
11:10AM  
10:20AM  
09:00AM  
07:02AM  
06:46AM  
Jul-23-20 05:50PM  
04:50PM  
01:30PM  
11:40AM  
08:35AM  
Jul-22-20 08:05PM  
07:00PM  
06:12PM  
04:45PM  
02:28PM  
01:00PM  
11:10AM  
10:10AM  
Jul-21-20 11:15AM  
10:09AM  
Sorrento Therapeutics, Inc., a clinical stage biopharma company, develops therapies for cancer, autoimmune, inflammatory, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutics by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugates, as well as bispecific antibody approaches. It also offers Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. In addition, the company's clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases. Further, it develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. Additionally, the company engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; and SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain conditions. It has various collaborations with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 86 patients with COVID-19; and Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection, as well as a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento's COVID-19 therapeutic product candidates. The company was founded in 2006 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Smith Robin LDirectorMar 05Buy2.2740,00090,89660,000Mar 05 01:58 PM